Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cardiff Oncology, Inc. (CRDF)
NASDAQ:CRDF
Holding CRDF?
Track your performance easily
Earnings Data
Report Date
Feb 27, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.25Last Year’s EPS
-$0.21Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 07, 2024
|% Change Since: 4.16%
|Next Earnings Date:Feb 27, 2025
Earnings Call Sentiment|Positive
The earnings call reflected an overall positive sentiment, with significant advancements in clinical trials and strong financial health. The company is making progress in its key trials and has a stable cash runway. While there were previous challenges in trial enrollment, these issues appear to be addressed.Company Guidance
During the second quarter 2024 earnings call for Cardiff Oncology (CRDF), the company provided several key updates and guidance on their ongoing clinical trials and financial status. The CRDF-004 trial, which targets RAS-mutated metastatic colorectal cancer (mCRC), is active in 33 sites with plans to enroll 90 patients. Cardiff Oncology expects an initial data readout later this year, which will include objective response rate data for approximately half of the enrolled patients. The company is also shifting its pancreatic cancer program to support a first-line investigator-initiated trial combining onvansertib with the newly approved standard of care regimen, Nal-IRI/5-FU/LV. Financially, Cardiff reported cash and short-term investments totaling $60.3 million as of June 30, 2024, with a cash runway projected through the third quarter of 2025. These developments underscore Cardiff's strategic focus on advancing onvansertib as a potential treatment across multiple cancer indications.CRDF-004 Trial Progress
The CRDF-004 trial for RAS-mutated mCRC is active in 33 sites, with plans to enroll 90 patients. Enrollment is on track, with initial data readout expected later this year. No new therapies have been approved for this patient population in the past 20 years, and there are no competing trials.
Pancreatic Cancer Program Update
The company is initiating a first-line investigator-initiated PDAC trial combining onvansertib with now [arifox], following the approval of [Nellyrefox] for first-line metastatic PDAC.
Preclinical Success in Ovarian Cancer
Recent preclinical studies show onvansertib's potential in overcoming resistance to PARP inhibitors in ovarian cancer, with promising in vitro and in vivo results.
Strong Financial Position
Cash and short-term investments total $60.3 million as of June 30, 2024, with a cash runway extending through Q3 2025.
---
CRDF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CRDF Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $4.09 | $3.08 | -24.69% |
| Aug 08, 2024 | $2.13 | $2.38 | +11.74% |
| May 02, 2024 | $4.48 | $3.52 | -21.43% |
| Feb 29, 2024 | $1.76 | $2.91 | +65.34% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Cardiff Oncology, Inc. (CRDF) report earnings?
Cardiff Oncology, Inc. (CRDF) is schdueled to report earning on Feb 27, 2025, TBA Not Confirmed.
What is Cardiff Oncology, Inc. (CRDF) earnings time?
Cardiff Oncology, Inc. (CRDF) earnings time is at Feb 27, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CRDF EPS forecast?
CRDF EPS forecast for the fiscal quarter 2024 (Q4) is -$0.25.
---